High-Dose Topotecan and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer

A Phase I Study of High Dose Topotecan With Filgrastim and Peripheral Blood Stem Cell Support for Patients With Refractory Malignancies

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00002948

Enrollment

Unknown

Registered

2003-01-27

Start date

1996-10-31

Completion date

2004-01-31

Last updated

2014-07-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Unspecified Adult Solid Tumor, Protocol Specific

Keywords

unspecified adult solid tumor, protocol specific

Brief summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of drugs and kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of high-dose topotecan and peripheral stem cell transplantation in treating patients with refractory cancer.

Detailed description

OBJECTIVES: * Determine the maximum tolerated dose, toxicities, and preliminary antitumor activity of escalating doses of topotecan, with filgrastim (G-CSF) and peripheral blood stem cell support, when administered to patients with refractory malignancies for which no effective therapy exists. OUTLINE: This is a dose-escalation study. Prior to stem cell harvesting, patients receive 1-2 courses of mobilizing salvage chemotherapy. After stem cell harvest, high-dose topotecan is administered according to an escalating dosage scale. Topotecan is given over 30 minutes daily for three days. A minimum of 3 patients are entered at each dose level. The MTD is defined as the dose immediately below that at which 2 patients experience dose limiting toxicity. Peripheral blood stem cells (PBSC) are infused at least 24 hours after treatment with topotecan is complete. Filgrastim (G-CSF) is administered subcutaneously beginning on the day PBSC are infused and continuing until blood counts recover. Patients are followed every 3 months for 1 year and then every 6 months thereafter. PROJECTED ACCRUAL: Not specified

Interventions

BIOLOGICALfilgrastim

DRUGtopotecan hydrochloride

PROCEDUREbone marrow ablation with stem cell support

PROCEDUREperipheral blood stem cell transplantation

Study design

Primary purpose

TREATMENT

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Histologically confirmed refractory malignancies for which no effective therapy is currently available PATIENT CHARACTERISTICS: Age: * Over 18 Performance status: * ECOG 0-2 Life expectancy: * At least 3 months Hematopoietic: * Platelet count at least 100,000/mm\^3 * Absolute neutrophil count at least 1,500/mm\^3 Hepatic: * Total bilirubin no greater than 2.0 mg/dL * No chronic active hepatitis Renal: * Creatinine clearance at least 60 mL/min Cardiovascular: * Left ventricular ejection fraction greater than 45% Pulmonary: * DLCO greater than 60% of predicted Other: * HIV negative * No active infection * No concurrent medical condition that would preclude therapy * Not pregnant or nursing * Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * At least 4 weeks since prior chemotherapy (6 weeks since prior nitrosoureas or mitomycin) Endocrine therapy: * Not specified Radiotherapy: * No radiotherapy to greater than 30% of bone marrow * No wide field radiotherapy Surgery: * Recovered from any prior surgery

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026